Michael C. Stephens, MD               

Titles
Program director, Inflammatory Bowel Disease, Children's Hospital of Wisconsin; assistant professor, Pediatrics, Medical College of Wisconsin.

Division
Gastroenterology and Nutrition

Research center/program
Clinical Pharmacology, Pharmacogenetics and Teratology

Research interests
Gastrointestinal diseases, genetic diseases/genomics, medications in children

Study interests
ABC transporters, developmental pharmacology, inflammatory bowel disease, pharmacogenetics.

Education
Medical degree, University of South Dakota School of Medicine, Vermillion, 1996; residency, University of Missouri, Columbia, 1999; fellowship, The Children's Hospital of Philadelphia, 2001.

Certifications
General Pediatrics, Pediatric Gastroenterology.

Honors
Young investigator award: World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, 2004.

Representative Publications:

• Stephens MC, Shepanski MA, Mamula P, Markowitz JE, Brown KA and Baldassano RN. Safety and Steroid-Sparing Experience Using Infliximab for Crohn's Disease at a Pediatric  Inflammatory Bowel Disease Center. American Journal of Gastroenterology. 2003; 98(1):104-11.
• Stephens MC, Baldassano RN, York A, Widemann B, Pitney AC, Jayaprakash N and Adamson PC. The Bioavailability of Oral Methotrexate in Children with Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition. 2005; 40(4):445-449.
• Hines RN, Koukouritaki SB, Poch MT and Stephens MC. Regulatory Polymorphisms and their Contribution to Interindividual Differences in the Expression of Enzymes Influencing Drug and Toxicant Disposition. Drug Metabolism Review. 2008; 40(2):263-301.
  

Grants

• ABC Transporter Pharmacogenetics: Impact on Thiopurine Therapy, National Institutes of Health, National Institute of General Medical Sciences.
• Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children with Crohn's Disease, Crohn's and Colitis Foundation of America.
• Genetic Markers as Predictors of Phenotypes in Pediatric Onset Crohn's Disease, Medical College of Wisconsin.
• A Phase 3 Randomized Open-Label Parallel-Group Multicenter Trial to Evaluate the Safety and Efficacy of Infliximab (REMICADE) in Pediatric Subjects with Moderately to Severly Active Ulcerative Colitis, Centocor, Inc.
• A Multi-Center, International, Observational Study of the Long-Term Safety of Infliximab (REMICADE) Results: Remicade Safety Under Long-Term Study, Centocor, Inc.
• A Multi-Center, Double-Blind Study to Evaluate the Safety, Efficacy and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects with Moderate to Severe Crohn's Disease, Abbott Laboratories.
• A Multi-Center Prospective, Long-term, Observational Registry of Pediatric Patients with Inflammatory Bowel Disease, Centocor, Inc.
• A Multi-Center International Study of the Long-Term Safety of Infliximab (REMICADE) in Ulcerative Colitis, Centocor, Inc.
• A Multi-Center, Open-Label Study of the Human AntiTNF Monoclonal Antibody Adalmumab to Evaluate the Tolerability of Repeated Administration of Adalimumab in Pediatric Subjects with Crohn's Disease Who Have demonstrated a Clinical Response in the M06-806 Study, Abbott Laboratories.

Contact
Children's Research Institute
8701 Watertown Plank Road
Wauwatosa, WI 53226
Phone: (414) 266-3690
Fax: (414) 266-3676